JP2017525755A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525755A5
JP2017525755A5 JP2017519448A JP2017519448A JP2017525755A5 JP 2017525755 A5 JP2017525755 A5 JP 2017525755A5 JP 2017519448 A JP2017519448 A JP 2017519448A JP 2017519448 A JP2017519448 A JP 2017519448A JP 2017525755 A5 JP2017525755 A5 JP 2017525755A5
Authority
JP
Japan
Prior art keywords
cancer
amino acid
linker
compound according
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017519448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525755A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/036414 external-priority patent/WO2015195904A1/en
Publication of JP2017525755A publication Critical patent/JP2017525755A/ja
Publication of JP2017525755A5 publication Critical patent/JP2017525755A5/ja
Pending legal-status Critical Current

Links

JP2017519448A 2014-06-20 2015-06-18 Her2抗体−薬物抱合体 Pending JP2017525755A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462014912P 2014-06-20 2014-06-20
US62/014,912 2014-06-20
US201462015661P 2014-06-23 2014-06-23
US62/015,661 2014-06-23
PCT/US2015/036414 WO2015195904A1 (en) 2014-06-20 2015-06-18 Her2 antibody-drug conjugates

Publications (2)

Publication Number Publication Date
JP2017525755A JP2017525755A (ja) 2017-09-07
JP2017525755A5 true JP2017525755A5 (enExample) 2018-07-26

Family

ID=54936097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519448A Pending JP2017525755A (ja) 2014-06-20 2015-06-18 Her2抗体−薬物抱合体

Country Status (16)

Country Link
US (1) US20160051695A1 (enExample)
EP (1) EP3157560A4 (enExample)
JP (1) JP2017525755A (enExample)
KR (1) KR20170063507A (enExample)
CN (1) CN106659783A (enExample)
AU (1) AU2015277100A1 (enExample)
BR (1) BR112016029588A2 (enExample)
CA (1) CA2952834A1 (enExample)
IL (1) IL249626A0 (enExample)
MX (1) MX2016017117A (enExample)
PH (1) PH12016502509A1 (enExample)
RU (1) RU2017101331A (enExample)
SG (2) SG11201610468XA (enExample)
TW (1) TW201625315A (enExample)
WO (1) WO2015195904A1 (enExample)
ZA (1) ZA201700306B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953106B2 (en) 2015-02-16 2021-03-23 Lonza Ltd Antibodies

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
KR20210132742A (ko) 2012-12-21 2021-11-04 알트루바이오 인코퍼레이티드 친수성 자기-희생 링커 및 그것의 포합체
KR20170020868A (ko) 2014-06-20 2017-02-24 바이오얼라이언스 씨.브이. 항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법
SI3313845T1 (sl) * 2015-06-29 2021-01-29 Immunogen, Inc. Konjugati spremenjenih protiteles cisteina
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11661438B2 (en) * 2015-12-21 2023-05-30 Pfizer, Inc. Purification of antibody drug conjugates using a sodium phosphate gradient
WO2017120534A1 (en) 2016-01-08 2017-07-13 Bioalliance C.V. Tetravalent anti-psgl-1 antibodies and uses thereof
CN107029244B (zh) * 2016-02-04 2021-04-27 浙江昭华生物医药有限公司 抗her2抗体-药物偶联物及其应用
SG11201907288RA (en) * 2017-02-28 2019-09-27 Seattle Genetics Inc Cysteine mutated antibodies for conjugation
CN110545850A (zh) 2017-03-10 2019-12-06 奎亚培格制药公司 可释放的缀合物
US20200155702A1 (en) * 2017-06-16 2020-05-21 Eli Lilly And Company Engineered Antibody Compounds and Conjuates Thereof
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
BR112020015071A2 (pt) * 2018-03-09 2021-01-05 Quiapeg Pharmaceuticals Ab Conjugados de anticorpos liberáveis
JP7193058B2 (ja) * 2018-08-08 2022-12-20 イミューンオンコ バイオファーマシューティカルズ (シャンハイ) インコーポレイテッド Cd47およびher2を標的とする組換え二機能性タンパク質
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
EP3849660A1 (en) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Releasable glp-1 conjugates
US12624063B2 (en) 2019-03-22 2026-05-12 The Regents Of The University Of California Compositions and methods for modification of target molecules
EP4114854A1 (en) * 2020-03-05 2023-01-11 UMC Utrecht Holding B.V. Membrane ubiquitin ligases to target protein degradation
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Preparations containing an antibody against HER2/NEU and their use
CN112618726B (zh) * 2020-12-21 2022-11-11 江南大学 一种抗体缀合物、增强抗体分子免疫效应功能的方法
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
LT4601703T (lt) 2023-04-18 2026-06-25 Astrazeneca Ab Konjugatai, apimantys atskeliamuosius jungtukus
EP4777491A2 (en) * 2023-09-11 2026-07-22 Catena Biosciences, Inc. Polypeptide conjugation compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2605443T3 (es) * 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CA2559870A1 (en) * 2004-04-07 2005-10-27 Genetech,Inc. Mass spectrometry of antibody conjugates
WO2010111018A1 (en) * 2009-03-06 2010-09-30 Agensys, Inc. Antibody drug conjugates (adc) that bind to 24p4c12 proteins
BRPI1015234A2 (en) * 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
PT2528625E (pt) * 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
NO3056203T3 (enExample) * 2010-04-21 2018-05-12
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
KR20210132742A (ko) * 2012-12-21 2021-11-04 알트루바이오 인코퍼레이티드 친수성 자기-희생 링커 및 그것의 포합체
EA201591465A1 (ru) * 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
DK2948184T3 (en) * 2014-01-10 2016-06-27 Synthon Biopharmaceuticals Bv Duocarmycin-ADCs with improved in vivo antitumor activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953106B2 (en) 2015-02-16 2021-03-23 Lonza Ltd Antibodies

Similar Documents

Publication Publication Date Title
RU2017101331A (ru) Конъюгаты антитело к her2 - лекарственное средство
US12285491B2 (en) Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
JP7853711B2 (ja) チューブリシン類縁体と細胞結合分子との共役体の製剤
JP2016508136A5 (enExample)
RU2017101662A (ru) Конъюгаты антитела против фолатного рецептора альфа (fra) c лекарственным средством и способы их применения
RU2015129800A (ru) Гидрофильные саморазрушающиеся линкеры и их конъюгаты
KR102655301B1 (ko) 비스-링키지를 사용한 세포독성 약물의 접합
RU2017101681A (ru) Конъюгаты анти-cd22 антитело - лекарственное средство и способы их применения
AU2023248079A1 (en) Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
KR20240095316A (ko) Bcma 단일클론 항체 및 항체-약물 접합체
JP2017528418A5 (enExample)
JP2024535637A5 (enExample)
JP2023530128A (ja) 細胞結合分子とカンプトテシン類縁体との共役体
JP2024510435A (ja) 生体活性化合物の内部移行複合体からの選択的薬物放出
JP2024511360A (ja) 生体活性化合物の内部移行複合体からの選択的薬物放出
JP2012522513A5 (enExample)
JP2012522512A5 (enExample)
JP2025508009A5 (enExample)
KR20210117302A (ko) 분지형 링커를 갖는 아마니타 독소의 접합체
CN105073988A (zh) 抗cdh3人源化抗体、其药剂偶联物以及它们的用途
WO2020065408A1 (en) Sulfomaleimide-based linkers and corresponding conjugates
JP2026508115A (ja) リンカー薬物、その抗体-薬物コンジュゲート、並びにそれらの調製方法及び使用
JP2025508779A5 (enExample)
CN117120098A (zh) 内化的生物活性化合物缀合物的选择性药物释放
CN117120097A (zh) 内化的生物活性化合物缀合物的选择性药物释放